An expansion for Trikafta, a drug used for the treatment of Cystic Fibrosis, to younger ages is an exciting development for those raising awareness of the condition.
Kasey McIntyre, who organizes the Walk to Make CF History in Estevan, says that this helps out a section of younger CF patients.
"If you have a copy of a gene of like a Delta F508 mutation you could be accepted into using this Trikafta. Now I know there are other trials you would need to go to to have it approved for you, but if you are part of the CF team in the province of Saskatchewan, they're already more than well aware that you have the right mutation to possibly get this access."
McIntyre says that more progress helps to make the work of those who raise awareness worth it.
"We've been advocating for that one for a couple of years now, but now that it has access in Saskatchewan, we know though that what we're doing is volunteers and advocates and raising awareness for this, this is pushing the efforts of medical breakthroughs like this for people to have access to it. Ao they're not just reading about it, hearing about it, it literally is happening today."
McIntyre says that the more people that get access to this, the more will lead happier, healthier lives, with fewer hospital trips or surgeries even if they're not cured.
Meanwhile, others without the Delta F508 mutation need different medications, which she's hoping could see a similar expansion in the future.
"Then there's still about 10 per cent of the population that will not have access to this breakthrough. So we have our own breakthrough that is not through Trikafta for my son Liam. Same company, he uses a Kalydeco and it has done wonders for him. So we hope and pray that what we've seen through him is the same for Trikafta for everyone.
"Then saying that with the 10 per cent that are left out, this is where we would say to keep going further. Because it's not done, it's not over. People haven't had their breakthrough yet and if I think about the families who are still fundraising and advocating and working so hard. To have their breakthrough and haven't got there yet, then our job is not done either."